Clinical Trial Update: Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg [Phase 4]

View source ↗

Summary

Phase 4 bioequivalence study comparing Palbociclib 125 mg capsules produced by Megalabs (Iclos) with the reference Ibrance 125 mg capsules (palbociclib).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• Iclos (palbociclib)

Snippet

Sponsor: Megalabs | Conditions: Bioequivalence | Phase 4 | Status: COMPLETED